Recent News

• 06.10.2026 - IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
• 06.09.2026 - IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
• 06.08.2026 - IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 06.03.2026 - IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
• 06.01.2026 - IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
• 05.29.2026 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 05.26.2026 - IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
• 05.05.2026 - IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Recent Filings

• 06.10.2026 - 8-K Current report
• 06.09.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.08.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.05.2026 - 3 Initial statement of beneficial ownership of securities
• 06.03.2026 - 8-K Current report
• 06.01.2026 - EX-99.1 EX-99.1
• 06.01.2026 - 8-K Current report
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.05.2026 - EX-99.1 EX-99.1
• 05.05.2026 - 8-K Current report